These results support the continued investigation of the role of SAA in metabolic diseases and also suggest that increased levels of SAA may be part of the signaling linking sleep loss to its associated comorbidities, such as obesity and type 2 diabetes. Here, SAA1 is linked to obesity due to melanocortin 4 receptor deficiency.